Traversing Frontline Treatment Decisions in EGFR-Mutated Non–Small Cell Lung Cancer

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss frontline treatment selection in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss how NCCN Guidelines can influence treatment decisions in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss trial data informing amivantamab use in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss the significance of the FDA approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss safety and toxicity management in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss ongoing research in EGFR-mutated NSCLC.